Moreover, a panel of nine flavonoids with SGK1 inhibitory activities was proposed, which can be used as valuable leads for the search and design of new therapeutics for cardiac hypertrophy as well as other SGK1‐driven diseases. This evidence concerns the gene SGK1 and cardiac hypertrophy.